Thomas A. Brandt
Pfizer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Thomas A. Brandt.
Journal of Medicinal Chemistry | 2011
Vincent Mascitti; Tristan S. Maurer; Ralph P. Robinson; Jianwei Bian; Carine M. Boustany-Kari; Thomas A. Brandt; Benjamin Micah Collman; Amit S. Kalgutkar; Michelle K. Klenotic; Michael T. Leininger; André Lowe; Robert John Maguire; Victoria M. Masterson; Zhuang Miao; Emi Mukaiyama; Jigna D. Patel; John C. Pettersen; Cathy Préville; Brian Samas; Li She; Zhanna Sobol; Claire M. Steppan; Benjamin D. Stevens; Benjamin A. Thuma; Meera Tugnait; Dongxiang Zeng; Tong Zhu
Compound 4 (PF-04971729) belongs to a new class of potent and selective sodium-dependent glucose cotransporter 2 inhibitors incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system. In this paper we present the design, synthesis, preclinical evaluation, and human dose predictions related to 4. This compound demonstrated robust urinary glucose excretion in rats and an excellent preclinical safety profile. It is currently in phase 2 clinical trials and is being evaluated for the treatment of type 2 diabetes.
Science | 2016
Ryan Gianatassio; Justin M. Lopchuk; Jie Wang; Chung-Mao Pan; Lara R. Malins; Liher Prieto; Thomas A. Brandt; Michael Raymond Collins; Gary M. Gallego; Neal W. Sach; Jillian E. Spangler; Huichin Zhu; Jinjiang Zhu; Phil S. Baran
Opening one ring to tack on another Curious chemists have long sought to learn just how tightly carbon atoms can be bound together. For instance, its possible to form a bond between two opposite corners of an already strained four-membered ring to make an edge-sharing pair of triangles. Gianatassio et al. have now devised a general use for these and related molecular curiosities. They show that appropriately modified nitrogen centers can pop open the most highly strained bond, leaving the more modestly strained ring motif intact. In this way, small rings can emerge as a convenient diversifying element in compounds, including new pharmaceutical candidates. Science, this issue p. 241 Strained rings are appended to compounds of pharmaceutical interest through the use of even more highly strained precursors. To optimize drug candidates, modern medicinal chemists are increasingly turning to an unconventional structural motif: small, strained ring systems. However, the difficulty of introducing substituents such as bicyclo[1.1.1]pentanes, azetidines, or cyclobutanes often outweighs the challenge of synthesizing the parent scaffold itself. Thus, there is an urgent need for general methods to rapidly and directly append such groups onto core scaffolds. Here we report a general strategy to harness the embedded potential energy of effectively spring-loaded C–C and C–N bonds with the most oft-encountered nucleophiles in pharmaceutical chemistry, amines. Strain-release amination can diversify a range of substrates with a multitude of desirable bioisosteres at both the early and late stages of a synthesis. The technique has also been applied to peptide labeling and bioconjugation.
Journal of the American Chemical Society | 2016
David W. Piotrowski; Adam S. Kamlet; Anne-Marie R. Dechert-Schmitt; Jiangli Yan; Thomas A. Brandt; Jun Xiao; Liuqing Wei; Mark T. Barrila
We report a modular three-component dynamic kinetic resolution (DKR) that affords enantiomerically enriched hemiaminal esters derived from azoles and aldehydes. The novel and scalable reaction can be used to synthesize valuable substituted azoles in a regioselective manner by capping (e.g., acylation) of the equilibrating azole-aldehyde adduct. With the use of a prolinol-derived DMAP catalyst as the chiral Lewis base, the products can be obtained in high chemical yield and with high enantiomeric excess. The DKR was performed on a multikilogram scale to produce a tetrazole prodrug fragment for a leading clinical candidate that posed formidable synthesis challenges.
MedChemComm | 2013
Vincent Mascitti; Benjamin A. Thuma; Aaron Smith; Ralph P. Robinson; Thomas A. Brandt; Amit S. Kalgutkar; Tristan S. Maurer; Brian Samas; Raman Sharma
The discovery of antidiabetic agent ertugliflozin is described. The compound belongs to a new class of SGLT2 inhibitors bearing a dioxa-bicyclo[3.2.1]octane motif. This article describes the critical role that organic synthesis played in both influencing our medicinal chemistry strategy and speeding up the progression of our program.
Journal of the American Chemical Society | 2017
Justin M. Lopchuk; Kasper Fjelbye; Yu Kawamata; Lara R. Malins; Chung-Mao Pan; Ryan Gianatassio; Jie Wang; Liher Prieto; James Bradow; Thomas A. Brandt; Michael Raymond Collins; Jeff Elleraas; Jason Ewanicki; William Farrell; Olugbeminiyi O. Fadeyi; Gary M. Gallego; James J. Mousseau; Robert Oliver; Neal W. Sach; Jason K. Smith; Jillian E. Spangler; Huichin Zhu; Jinjiang Zhu; Phil S. Baran
Driven by the ever-increasing pace of drug discovery and the need to push the boundaries of unexplored chemical space, medicinal chemists are routinely turning to unusual strained bioisosteres such as bicyclo[1.1.1]pentane, azetidine, and cyclobutane to modify their lead compounds. Too often, however, the difficulty of installing these fragments surpasses the challenges posed even by the construction of the parent drug scaffold. This full account describes the development and application of a general strategy where spring-loaded, strained C–C and C–N bonds react with amines to allow for the “any-stage” installation of small, strained ring systems. In addition to the functionalization of small building blocks and late-stage intermediates, the methodology has been applied to bioconjugation and peptide labeling. For the first time, the stereospecific strain-release “cyclopentylation” of amines, alcohols, thiols, carboxylic acids, and other heteroatoms is introduced. This report describes the development, synthesis, scope of reaction, bioconjugation, and synthetic comparisons of four new chiral “cyclopentylation” reagents.
Journal of Chemical Research-s | 2006
Bryan Li; Michael F. Witt; Thomas A. Brandt; David C. Whritenour
A streamlined process for the synthesis of 3-amino-1-benzhydrylazetidine is described. Commercially available 1-benzhydrylazetidin-3-ol was reacted with methanesulfonyl chloride in the presence of triethylamine in acetonitrile, upon quench with water, the mesylate intermediate (3) was isolated by filtration. The wet filter cake was subsequently treated with ammonium hydroxide/isopropanol in a Parr reactor at ∼70°C. The procedure afforded the titled compound as mono acetate salt in 72–84% yield.
Organic Process Research & Development | 2005
David H. Brown Ripin; Dennis E. Bourassa; Thomas A. Brandt; Michael J. Castaldi; Heather N. Frost; Joel M. Hawkins; Phillip J. Johnson; Stephen S. Massett; Karin Neumann; James Phillips; Jeffery W. Raggon; Peter Robert Rose; Jennifer L. Rutherford; Barbara J. Sitter; A. Morgan Stewart; Michael G. Vetelino; Lulin Wei
Organic Process Research & Development | 2014
David Bernhardson; Thomas A. Brandt; Catherine A. Hulford; Richard Shelton Lehner; Brian R. Preston; Kristin Price; John F. Sagal; Michael J. St. Pierre; Peter H. Thompson; Benjamin A. Thuma
Tetrahedron | 2009
Thomas A. Brandt; Stephane Caron; David B. Damon; Joseph DiBrino; Arun Ghosh; David A. Griffith; Sandeep Kedia; John A. Ragan; Peter Robert Rose; Brian C. Vanderplas; Lulin Wei
Archive | 2003
Scott W. Bagley; Thomas A. Brandt; Robert W. Dugger; William A. Hada; Cheryl Myers Hayward; Zhengyu Liu